The NF-κB-suppressing effects of glomerular PPARα might be useful for the treatment of the various types of glomerulonephritis, including MsPGN, immune complex kidney disease, crescentic glomerulonephritis, and lupus nephritis, as well as metabolic abnormality-based glomerulonephropathy. This evidence concerns the gene NFKB1 and crescentic glomerulonephritis.